#11368. Progressive deterioration of frailty is associated with poor outcomes in patients with transthyretin cardiac amyloidosis

July 2026publication date
Proposal available till 24-05-2025
4 total number of authors per manuscript0 $

The title of the journal is available only for the authors who have already paid for
Journal’s subject area:
Health (social science);
Gerontology;
Geriatrics and Gerontology;
Places in the authors’ list:
place 1place 2place 3place 4
FreeFreeFreeFree
2350 $1200 $1050 $900 $
Contract №11368.1 Contract №11368.2 Contract №11368.3 Contract №11368.4
1 place - free (for sale)
2 place - free (for sale)
3 place - free (for sale)
4 place - free (for sale)

Abstract:
Progressive deterioration of frailty is associated with poor outcomes in patients with transthyretin cardiac amyloidosis. Transthyretin amyloidosis (ATTR amyloidosis) is a heterogeneous disorder with cardiac, neurologic, and mixed phenotypes. We describe the phenotypic and genotypic profiles of this disease as it appears from the Transthyretin Amyloidosis Survey (THAOS). ATTR amyloidosis genotypes and phenotypes are highly heterogeneous. A geographic map of the different disease profiles and awareness that a subset of subjects have a dominant cardiac phenotype, mimicking hypertrophic cardiomyopathy, at presentation can facilitate the clinical recognition of this underdiagnosed disease. THAOS is an ongoing, worldwide, longitudinal, observational survey established to study differences in presentation, diagnosis, and natural history in ATTR amyloidosis subjects. At data cut-off, 1411 symptomatic subjects from nine countries were enrolled in THAOS. Genotypes and phenotypes varied notably by country. Subjects with cardiac mutations had a lower survival rate than subjects in other genotype (or the neurologic phenotype) categories.
Keywords:
Transthyretin cardiac amyloidosis; heterogeneous disorder; progressive deterioration; phenotypic and genotypic profiles

Contacts :
0